Phase 2 N=279 Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
Breast Cancer · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) — 58.1; 57.9 percent ejected from LV per heartbeat — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=176 Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
Preeclampsia · Labor, Premature
Primary: Cesarean Delivery Rate — 29; 22 Participants
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=150 A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Primary: Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection — 35.6; 35.6; 5.5; 0 Percentage of Paticipants — p=0.307
Phase 4 N=477 Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year
Asthma
Primary: Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry — 6.065; 5.905 Centimeter per year
Phase 2 N=66 Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity
Severe Obesity
Primary: Body Mass Index — 10.1; 4.6 percentage (body mass index)
Phase 1 N=30 Modeling Mood Course to Detect Markers for Effective Adaptive Interventions- Aim 3
Bipolar Disorder · Psychosocial Intervention
Primary: Number of Shortened YMRS Surveys Completed — 1651 completed surveys
N/A N=66 Social Media Indoor Tanning Study
Skin Cancer
Primary: Recruitment — 549; 79; 66 Participants
Phase 2 N=12 E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI…
N/A N=584 Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)
Left Ventricular Dysfunction
Primary: LV MSP Feature Related Complication-Free Rate — 99 percentage of participants
N/A N=12 Comparing Pro-Inflammatory Cytokines and Bone Metabolism Mediators Around Laser-Lok and Machined Transmucosal Abutments
Dental Implants
Primary: Difference in PICF Cytokine Levels (Log pg/ml) for Various Biomarkers, Specifically at Laser-Lok Abutment Sites and Machined Abutment Sites at 8 Weeks After Implant…
Phase 1 N=241 Flublok or Fluzone With Advax-CpG55.2 or AF03
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Phase 2 N=237 S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Bladder Cancer
Primary: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate — 8; 10; 20; 17 Participants — p=0.1
Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
Phase 3 N=60 A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma
Exercise Induced Bronchospasm
Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 5.45…